<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Transplant Direct</journal-id><journal-id journal-id-type="iso-abbrev">Transplant Direct</journal-id><journal-id journal-id-type="publisher-id">TXD</journal-id><journal-title-group><journal-title>Transplantation Direct</journal-title></journal-title-group><issn pub-type="epub">2373-8731</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28361113</article-id><article-id pub-id-type="pmc">5367746</article-id><article-id pub-id-type="publisher-id">TXD50119</article-id><article-id pub-id-type="doi">10.1097/TXD.0000000000000644</article-id><article-id pub-id-type="art-access-id">00004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Andrews</surname><given-names>Louise M.</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Winter</surname><given-names>Brenda C.M.</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Jiang-Tao</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shuker</surname><given-names>Nauras</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bouamar</surname><given-names>Rachida</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Schaik</surname><given-names>Ron H.N.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Koch</surname><given-names>Birgit C.P.</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Gelder</surname><given-names>Teun</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1 aff4"><sup>1,4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hesselink</surname><given-names>Dennis A.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup> Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.</aff><aff id="aff2"><sup>2</sup> Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.</aff><aff id="aff3"><sup>3</sup> Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.</aff><aff id="aff4"><sup>4</sup> Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.</aff><author-notes><corresp id="cor1">Correspondence: Louise Andrews, PharmD, Department of Hospital Pharmacy, Erasmus MC, University, Medical Center Rotterdam, Room Na-206, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands. (<email>l.andrews@erasmusmc.nl</email>).</corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>19</day><month>1</month><year>2017</year></pub-date><volume>3</volume><issue>2</issue><elocation-id>e129</elocation-id><history><date date-type="received"><day>19</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2017 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="txd-3-e129.pdf"></self-uri><abstract><sec><title><offsets xml_i="5085" xml_f="5095" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5106" xml_f="5369" txt_i="22" txt_f="285">Bodyweight-based dosing of tacrolimus (Tac) is considered standard care, even though the available evidence is thin. An increasing proportion of transplant recipients is overweight, prompting the question if the starting dose should always be based on bodyweight.</offsets></p></sec><sec><title><offsets xml_i="5391" xml_f="5398" txt_i="287" txt_f="294">Methods</offsets></title><p><offsets xml_i="5409" xml_f="5569" txt_i="295" txt_f="455">For this analysis, data were used from a randomized-controlled trial in which patients received either a standard Tac starting dose or a dose that was based on </offsets><italic><offsets xml_i="5577" xml_f="5583" txt_i="455" txt_f="461">CYP3A5</offsets></italic><offsets xml_i="5592" xml_f="5718" txt_i="461" txt_f="587"> genotype. The hypothesis was that overweight patients would have Tac overexposure following standard bodyweight-based dosing.</offsets></p></sec><sec><title><offsets xml_i="5740" xml_f="5747" txt_i="589" txt_f="596">Results</offsets></title><p><offsets xml_i="5758" xml_f="6346" txt_i="597" txt_f="1185">Data were available for 203 kidney transplant recipients, with a median body mass index (BMI) of 25.6 (range, 17.2-42.2). More than 50% of the overweight or obese patients had a Tac predose concentration above the target range. The CYP3A5 nonexpressers tended to be above target when they weighed more than 67.5 kg or had a BMI of 24.5 or higher. Dosing guidelines were proposed with a decrease up to 40% in Tac starting doses for different BMI groups. The dosing guideline for patients with an unknown genotype was validated using the fixed-dose versus concentration controlled data set.</offsets></p></sec><sec><title><offsets xml_i="6368" xml_f="6379" txt_i="1187" txt_f="1198">Conclusions</offsets></title><p><offsets xml_i="6390" xml_f="6525" txt_i="1199" txt_f="1334">This study demonstrates that dosing Tac solely on bodyweight results in overexposure in more than half of overweight or obese patients.</offsets></p></sec></abstract><counts><page-count count="0"></page-count></counts><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="6759" xml_f="6894" txt_i="1343" txt_f="1478">The oral starting dose of tacrolimus (Tac) in the first trial in humans was 0.15 mg/kg. This starting dose was based on animal studies.</offsets><sup><xref rid="bib1" ref-type="bibr"><offsets xml_i="6932" xml_f="6933" txt_i="1478" txt_f="1479">1</offsets></xref><offsets xml_i="6940" xml_f="6941" txt_i="1479" txt_f="1480">,</offsets><xref rid="bib2" ref-type="bibr"><offsets xml_i="6974" xml_f="6975" txt_i="1480" txt_f="1481">2</offsets></xref></sup><offsets xml_i="6988" xml_f="7158" txt_i="1481" txt_f="1651"> A few years later, in most transplant centers, oral Tac therapy was initiated with doses ranging from 0.10 to 0.20 mg/kg per day administered in 2 equally divided doses.</offsets><sup><xref rid="bib3" ref-type="bibr"><offsets xml_i="7196" xml_f="7197" txt_i="1651" txt_f="1652">3</offsets></xref></sup><offsets xml_i="7210" xml_f="7264" txt_i="1652" txt_f="1706"> This recommended starting dose has not changed since.</offsets><sup><xref rid="bib4" ref-type="bibr"><offsets xml_i="7302" xml_f="7303" txt_i="1706" txt_f="1707">4</offsets></xref></sup></p><p><offsets xml_i="7323" xml_f="7406" txt_i="1708" txt_f="1791">Tac has a narrow therapeutic window and displays large pharmacokinetic variability.</offsets><sup><xref rid="bib5" ref-type="bibr"><offsets xml_i="7444" xml_f="7445" txt_i="1791" txt_f="1792">5</offsets></xref></sup><offsets xml_i="7458" xml_f="7561" txt_i="1792" txt_f="1895"> Even with therapeutic drug monitoring (TDM), it can take up to 14 days to reach target concentrations.</offsets><sup><xref rid="bib6" ref-type="bibr"><offsets xml_i="7599" xml_f="7600" txt_i="1895" txt_f="1896">6</offsets></xref></sup><offsets xml_i="7613" xml_f="7765" txt_i="1896" txt_f="2048"> In theory, the sooner target Tac concentrations are attained post transplantation, the more effective it is likely to be in preventing acute rejection.</offsets><sup><xref rid="bib1" ref-type="bibr"><offsets xml_i="7803" xml_f="7804" txt_i="2048" txt_f="2049">1</offsets></xref></sup><offsets xml_i="7817" xml_f="7981" txt_i="2049" txt_f="2213"> Previous studies have suggested that underexposure of Tac could be related to low bodyweight and overexposure to higher bodyweight in kidney transplant recipients.</offsets><sup><xref rid="bib7" ref-type="bibr"><offsets xml_i="8019" xml_f="8020" txt_i="2213" txt_f="2214">7</offsets></xref><offsets xml_i="8027" xml_f="8028" txt_i="2214" txt_f="2215">-</offsets><xref rid="bib10" ref-type="bibr"><offsets xml_i="8062" xml_f="8064" txt_i="2215" txt_f="2217">10</offsets></xref></sup><offsets xml_i="8077" xml_f="8228" txt_i="2217" txt_f="2368"> Available data suggests that being overweight or obese at time of kidney transplantation has a negative effect on both patient and allograft outcomes.</offsets><sup><xref rid="bib11" ref-type="bibr"><offsets xml_i="8267" xml_f="8269" txt_i="2368" txt_f="2370">11</offsets></xref></sup><offsets xml_i="8282" xml_f="8531" txt_i="2370" txt_f="2619"> Overweight kidney transplant recipients have an increased mortality, more delayed graft functions, more acute rejection episodes, more wound infections, and a longer hospital stay compared with patients with a body mass index (BMI) of less than 30.</offsets><sup><xref rid="bib12" ref-type="bibr"><offsets xml_i="8570" xml_f="8572" txt_i="2619" txt_f="2621">12</offsets></xref></sup><offsets xml_i="8585" xml_f="8735" txt_i="2621" txt_f="2771"> The kidney disease improving global outcomes Transplant Workgroup states that dosing of Tac is important and that it is relatively underinvestigated.</offsets><sup><xref rid="bib1" ref-type="bibr"><offsets xml_i="8773" xml_f="8774" txt_i="2771" txt_f="2772">1</offsets></xref></sup><offsets xml_i="8787" xml_f="8980" txt_i="2772" txt_f="2965"> Although the Tac starting dose is based on bodyweight in many centers, dosing algorithms have demonstrated that bodyweight does not have a statistically significant influence on Tac clearance.</offsets><sup><xref rid="bib13" ref-type="bibr"><offsets xml_i="9019" xml_f="9021" txt_i="2965" txt_f="2967">13</offsets></xref><offsets xml_i="9028" xml_f="9029" txt_i="2967" txt_f="2968">,</offsets><xref rid="bib14" ref-type="bibr"><offsets xml_i="9063" xml_f="9065" txt_i="2968" txt_f="2970">14</offsets></xref></sup><offsets xml_i="9078" xml_f="9166" txt_i="2970" txt_f="3058"> The evidence that Tac elimination is linearly related to total bodyweight remains thin.</offsets></p><p><offsets xml_i="9173" xml_f="9313" txt_i="3059" txt_f="3199">In 2003, the majority (60%) of kidney transplant recipients were overweight (BMI, 25-30) or obese (BMI ≥ 30) at the time of transplantation.</offsets><sup><xref rid="bib11" ref-type="bibr"><offsets xml_i="9352" xml_f="9354" txt_i="3199" txt_f="3201">11</offsets></xref></sup><offsets xml_i="9367" xml_f="9702" txt_i="3201" txt_f="3536"> With global obesity on the rise, this number is likely to increase even further and prompts the question if it is justified to continue to base the Tac starting dose on bodyweight. In this study, we investigated whether Tac dosing based on bodyweight leads to the achievement of Tac target whole-blood exposure in overweight patients.</offsets></p><sec sec-type="methods"><title><offsets xml_i="9737" xml_f="9758" txt_i="3537" txt_f="3558">MATERIALS AND METHODS</offsets></title><sec><title><offsets xml_i="9778" xml_f="9782" txt_i="3559" txt_f="3563">Aims</offsets></title><p><offsets xml_i="9793" xml_f="9958" txt_i="3564" txt_f="3729">The aim of this study was to investigate whether a Tac starting dose based on bodyweight leads to the achievement of Tac target whole-blood predose concentrations (C</offsets><sub><offsets xml_i="9963" xml_f="9964" txt_i="3729" txt_f="3730">0</offsets></sub><offsets xml_i="9970" xml_f="10190" txt_i="3730" txt_f="3950">) in overweight patients on day 3 after transplantation. This was defined as the first steady state concentration attained after 5 unaltered Tac doses. The subsequent dose was determined using TDM. The prespecified Tac C</offsets><sub><offsets xml_i="10195" xml_f="10196" txt_i="3950" txt_f="3951">0</offsets></sub><offsets xml_i="10202" xml_f="10384" txt_i="3951" txt_f="4133"> target range was 10 to 15 ng/mL. The hypothesis was that overweight patients are overdosed if the starting dose is strictly based on bodyweight alone. Furthermore, the influence of </offsets><italic><offsets xml_i="10392" xml_f="10398" txt_i="4133" txt_f="4139">CYP3A5</offsets></italic><offsets xml_i="10407" xml_f="10499" txt_i="4139" txt_f="4231"> genotype on the relationship between bodyweight (or BMI) and Tac exposure was investigated.</offsets></p></sec><sec sec-type="subjects"><title><offsets xml_i="10541" xml_f="10549" txt_i="4233" txt_f="4241">Patients</offsets></title><p><offsets xml_i="10560" xml_f="10742" txt_i="4242" txt_f="4424">The patients in this study were kidney transplant recipients who participated in a randomized-controlled trial investigating whether adaptation of the Tac starting dose according to </offsets><italic><offsets xml_i="10750" xml_f="10756" txt_i="4424" txt_f="4430">CYP3A5</offsets></italic><offsets xml_i="10765" xml_f="11109" txt_i="4430" txt_f="4774"> genotype increases the proportion of kidney transplant recipients reaching the target Tac predose concentration range (10-15 ng/mL) at first steady-state. After day 3, the physicians were allowed to adapt the Tac dose based on whole-blood concentration measurements. The primary outcomes of this trial were presented in a separate publication.</offsets><sup><xref rid="bib15" ref-type="bibr"><offsets xml_i="11148" xml_f="11150" txt_i="4774" txt_f="4776">15</offsets></xref></sup></p><p><offsets xml_i="11170" xml_f="11325" txt_i="4777" txt_f="4932">In this trial, patients were randomized to receive Tac in either the standard, bodyweight-based dose of 0.20 mg/kg per day according to the package insert,</offsets><sup><xref rid="bib4" ref-type="bibr"><offsets xml_i="11363" xml_f="11364" txt_i="4932" txt_f="4933">4</offsets></xref></sup><offsets xml_i="11377" xml_f="11414" txt_i="4933" txt_f="4970"> or to receive a dose based on their </offsets><italic><offsets xml_i="11422" xml_f="11428" txt_i="4970" txt_f="4976">CYP3A5</offsets></italic><offsets xml_i="11437" xml_f="11490" txt_i="4976" txt_f="5029"> genotype. CYP3A5 expressers (ie, carriers of 1 or 2 </offsets><italic><offsets xml_i="11498" xml_f="11506" txt_i="5029" txt_f="5037">CYP3A5*1</offsets></italic><offsets xml_i="11515" xml_f="11581" txt_i="5037" txt_f="5103"> alleles) received 0.30 mg/kg per day, whereas the nonexpressers (</offsets><italic><offsets xml_i="11589" xml_f="11597" txt_i="5103" txt_f="5111">CYP3A5*3</offsets></italic><offsets xml_i="11606" xml_f="11787" txt_i="5111" txt_f="5292"> homozygotes) received 0.15 mg/kg per day. The additional immunosuppressive therapy was identical for all patients and consisted of basiliximab, mycophenolic acid, and prednisolone.</offsets><sup><xref rid="bib15" ref-type="bibr"><offsets xml_i="11826" xml_f="11828" txt_i="5292" txt_f="5294">15</offsets></xref></sup><offsets xml_i="11841" xml_f="11943" txt_i="5294" txt_f="5396"> The only inclusion criteria for the post hoc analysis presented here was that there had to be a Tac C</offsets><sub><offsets xml_i="11948" xml_f="11949" txt_i="5396" txt_f="5397">0</offsets></sub><offsets xml_i="11955" xml_f="11997" txt_i="5397" txt_f="5439"> available on day 3 after transplantation.</offsets></p></sec><sec><title><offsets xml_i="12019" xml_f="12048" txt_i="5441" txt_f="5470">Tac Concentration Measurement</offsets></title><p><offsets xml_i="12059" xml_f="12083" txt_i="5471" txt_f="5495">As described previously,</offsets><sup><xref rid="bib15" ref-type="bibr"><offsets xml_i="12122" xml_f="12124" txt_i="5495" txt_f="5497">15</offsets></xref></sup><offsets xml_i="12137" xml_f="12147" txt_i="5497" txt_f="5507"> the Tac C</offsets><sub><offsets xml_i="12152" xml_f="12153" txt_i="5507" txt_f="5508">0</offsets></sub><offsets xml_i="12159" xml_f="12920" txt_i="5508" txt_f="6269"> was measured in the laboratory of the Erasmus MC using 2 different immunoassays: antibody-conjugated magnetic immunoassay (ACMIA) and enzyme multiplied immunoassay technique (EMIT). The measurements obtained with EMIT were systematically approximately 15% higher than those obtained with ACMIA. The weight of patients measured with the 2 different assays was not significantly different. The mean weight of the patients measured with ACMIA was 79.6 kg (95% confidence interval, 77-82.2 kg) and for EMIT 78.4 kg (95% confidence interval, 74-82.9 kg). The lower limits of detection were 1.5 ng/mL (ACMIA) and 2.0 ng/mL (EMIT). In this study, the lowest Tac concentration was 2.6 ng/mL. The upper limit of detection was 30.0 ng/mL. For calculation purposes, Tac C</offsets><sub><offsets xml_i="12925" xml_f="12926" txt_i="6269" txt_f="6270">0</offsets></sub><offsets xml_i="12932" xml_f="13091" txt_i="6270" txt_f="6429"> above the detection limit was set at 30.0 ng/mL. For further details on the Tac concentration measurement, the reader is referred to our previous publication.</offsets><sup><xref rid="bib15" ref-type="bibr"><offsets xml_i="13130" xml_f="13132" txt_i="6429" txt_f="6431">15</offsets></xref></sup></p></sec><sec><title><offsets xml_i="13167" xml_f="13184" txt_i="6433" txt_f="6450">Dosing Guidelines</offsets></title><p><offsets xml_i="13195" xml_f="13376" txt_i="6451" txt_f="6632">Dosing guidelines were developed and validated retrospectively in an independent cohort of patients that participated in the fixed-dose versus concentration controlled (FDCC) study.</offsets><sup><xref rid="bib16" ref-type="bibr"><offsets xml_i="13415" xml_f="13417" txt_i="6632" txt_f="6634">16</offsets></xref></sup><offsets xml_i="13430" xml_f="13681" txt_i="6634" txt_f="6885"> All Tac concentrations were scaled to the theoretical starting dose of 0.2 mg/kg. The percentage of patients on target and the median Tac concentration on day 3 after transplantation were compared before and after utilization of the dosing guideline.</offsets></p></sec><sec><title><offsets xml_i="13703" xml_f="13723" txt_i="6887" txt_f="6907">Statistical Analysis</offsets></title><p><offsets xml_i="13734" xml_f="13980" txt_i="6908" txt_f="7154">For the analysis, the data were divided into 3 groups: the standard-dose group (SDG), the genotype-based group (GBG), and all patients (SDG plus GBG) scaled to the standard bodyweight dose. The latter group was created to be able to compare the C</offsets><sub><offsets xml_i="13985" xml_f="13986" txt_i="7154" txt_f="7155">0</offsets></sub><offsets xml_i="13992" xml_f="14100" txt_i="7155" txt_f="7263"> of all patients, irrespective of whether the starting dose was adjusted according to genotype. The scaled C</offsets><sub><offsets xml_i="14105" xml_f="14106" txt_i="7263" txt_f="7264">0</offsets></sub><offsets xml_i="14112" xml_f="14145" txt_i="7264" txt_f="7297"> was calculated by dividing the C</offsets><sub><offsets xml_i="14150" xml_f="14151" txt_i="7297" txt_f="7298">0</offsets></sub><offsets xml_i="14157" xml_f="14496" txt_i="7298" txt_f="7637"> by the actual dose per kg bodyweight and multiplying this by 0.2. Categorical variables are reported using frequency tables and percentages, and continuous variables are expressed as medians with ranges. Tac overexposure was defined as a Tac concentration above 15 ng/mL, and underexposure as below 10 ng/mL. The correlation between Tac C</offsets><sub><offsets xml_i="14501" xml_f="14502" txt_i="7637" txt_f="7638">0</offsets></sub><offsets xml_i="14508" xml_f="14765" txt_i="7638" txt_f="7895"> and bodyweight (or BMI) was investigated by calculating the goodness of fit. Dosing guidelines were calculated using linear regression lines. Descriptive statistics were generated, and all tests were 2-tailed, and statistical significance was defined as a </offsets><italic><offsets xml_i="14773" xml_f="14774" txt_i="7895" txt_f="7896">P</offsets></italic><offsets xml_i="14783" xml_f="14876" txt_i="7896" txt_f="7989"> value less than 0.05. Data were analyzed using IBM SPSS version 21 (SPSS Inc., Chicago, IL).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="14923" xml_f="14930" txt_i="7992" txt_f="7999">RESULTS</offsets></title><p><offsets xml_i="14941" xml_f="15105" txt_i="8000" txt_f="8164">For this post hoc analysis, data were available for 203 kidney transplant recipients. A total of 34 patients were not included in this analysis because no data on C</offsets><sub><offsets xml_i="15110" xml_f="15111" txt_i="8164" txt_f="8165">0</offsets></sub><offsets xml_i="15117" xml_f="15231" txt_i="8165" txt_f="8279"> was available on day 3 after transplantation due to logistic issues (usually missed sample collection on Sunday).</offsets><sup><xref rid="bib15" ref-type="bibr"><offsets xml_i="15270" xml_f="15272" txt_i="8279" txt_f="8281">15</offsets></xref></sup><offsets xml_i="15285" xml_f="15337" txt_i="8281" txt_f="8333"> The patient characteristics are described in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="15369" xml_f="15370" txt_i="8333" txt_f="8334">1</offsets></xref><offsets xml_i="15377" xml_f="15483" txt_i="8334" txt_f="8440">. The median bodyweight was 78.9 kg with a range of 37.6 to 123.1 kg, whereas the median BMI was 25.6 kg/m</offsets><sup><offsets xml_i="15488" xml_f="15489" txt_i="8440" txt_f="8441">2</offsets></sup><offsets xml_i="15495" xml_f="15529" txt_i="8441" txt_f="8475"> with a range of 17.2 to 42.2 kg/m</offsets><sup><offsets xml_i="15534" xml_f="15535" txt_i="8475" txt_f="8476">2</offsets></sup><offsets xml_i="15541" xml_f="15687" txt_i="8476" txt_f="8613">. Of all patients, 102 (50.2%) were overweight (BMI &gt; 25), 40 (19.7%) were obese (BMI &gt; 30), and 1 patient was morbidly obese (BMI &gt; 40).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="15735" xml_f="15742" txt_i="8614" txt_f="8621">TABLE 1</offsets></label><caption><p><offsets xml_i="15762" xml_f="15785" txt_i="8621" txt_f="8644">Patient characteristics</offsets></p></caption><graphic xlink:href="txd-3-e129-g001"></graphic></table-wrap><sec><title><offsets xml_i="15872" xml_f="15882" txt_i="8645" txt_f="8655">Bodyweight</offsets></title><p><offsets xml_i="15893" xml_f="15973" txt_i="8656" txt_f="8736">In the SDG, the overweight or obese patients had significant higher median Tac C</offsets><sub><offsets xml_i="15978" xml_f="15979" txt_i="8736" txt_f="8737">0</offsets></sub><offsets xml_i="15985" xml_f="16089" txt_i="8737" txt_f="8841"> (15.9 ng/mL) after 5 unaltered Tac doses than patients with a BMI smaller than 25 (12.0 ng/mL), with a </offsets><italic><offsets xml_i="16097" xml_f="16098" txt_i="8841" txt_f="8842">P</offsets></italic><offsets xml_i="16107" xml_f="16233" txt_i="8842" txt_f="8968"> value of 0.011. Of the overweight or obese patients, 57.8% were overexposed. The CYP3A5 expressers on average had lower Tac C</offsets><sub><offsets xml_i="16238" xml_f="16239" txt_i="8968" txt_f="8969">0</offsets></sub><offsets xml_i="16245" xml_f="16303" txt_i="8969" txt_f="9027"> than the CYP3A5 nonexpressers (10.7 ng/mL vs 16.2 ng/mL, </offsets><italic><offsets xml_i="16311" xml_f="16312" txt_i="9027" txt_f="9028">P</offsets></italic><offsets xml_i="16321" xml_f="16437" txt_i="9028" txt_f="9144"> = 0.001). On day 3 after transplantation, a considerable proportion (47%) of nonexpressers was overexposed (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="16467" xml_f="16468" txt_i="9144" txt_f="9145">1</offsets></xref><offsets xml_i="16475" xml_f="16527" txt_i="9145" txt_f="9197">A). In CYP3A5 expressers, only 13% was overexposed (</offsets><italic><offsets xml_i="16535" xml_f="16536" txt_i="9197" txt_f="9198">P</offsets></italic><offsets xml_i="16545" xml_f="16555" txt_i="9198" txt_f="9208"> = 0.003).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="16596" xml_f="16604" txt_i="9209" txt_f="9217">FIGURE 1</offsets></label><caption><p><offsets xml_i="16624" xml_f="16660" txt_i="9217" txt_f="9253">The association between bodyweight, </offsets><italic><offsets xml_i="16668" xml_f="16674" txt_i="9253" txt_f="9259">CYP3A5</offsets></italic><offsets xml_i="16683" xml_f="16702" txt_i="9259" txt_f="9278"> genotype and Tac C</offsets><sub><offsets xml_i="16707" xml_f="16708" txt_i="9278" txt_f="9279">0</offsets></sub><offsets xml_i="16714" xml_f="17009" txt_i="9279" txt_f="9574"> on day 3 after transplantation, with the target concentration of 10 to 15 ng/mL shown (shaded area). A, Patients who received 0.20 mg/kg Tac. B, Patients who received Tac in a dose of 0.15 mg/kg (CYP3A5 nonexpressers) or 0.30 mg/kg (CYP3A5 expressers). C, All patients scaled to 0.2 mg/kg dose.</offsets></p></caption><graphic xlink:href="txd-3-e129-g002"></graphic></fig><p><offsets xml_i="17080" xml_f="17087" txt_i="9575" txt_f="9582">Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="17117" xml_f="17118" txt_i="9582" txt_f="9583">1</offsets></xref><offsets xml_i="17125" xml_f="17178" txt_i="9583" txt_f="9636">B shows the relationship between bodyweight and Tac C</offsets><sub><offsets xml_i="17183" xml_f="17184" txt_i="9636" txt_f="9637">0</offsets></sub><offsets xml_i="17190" xml_f="17473" txt_i="9637" txt_f="9920"> in the GBG. In this group, all nonexpressers received 0.15 mg/kg and the expressers 0.30 mg/kg. Of all patients dosed according to genotype, 35.4% of all overweight or obese patients were overexposed. Of all patients in this group, 30% was overexposed, whereas 35% was underexposed.</offsets></p><p><offsets xml_i="17480" xml_f="17487" txt_i="9921" txt_f="9928">Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="17517" xml_f="17518" txt_i="9928" txt_f="9929">1</offsets></xref><offsets xml_i="17525" xml_f="18067" txt_i="9929" txt_f="10471">C depicts all patients in the study scaled to the theoretical dose of 0.2 mg/kg per day. Due to scaling of the dose, the maximum Tac concentration depicted in the figure increased to 38.5 ng/mL, rather than the 30 ng/mL cutoff. Of all overweight or obese patients, 53.6% were overexposed. In line with the SDG, a substantial proportion of nonexpressers was above the target range (36%) and over a quarter (27%) was underexposed. The correlation line crosses the upper limit of the target range at 67.5 kg (calculated with the regression line </offsets><italic><offsets xml_i="18075" xml_f="18076" txt_i="10471" txt_f="10472">y</offsets></italic><offsets xml_i="18085" xml_f="18092" txt_i="10472" txt_f="10479"> = 0.12</offsets><italic><offsets xml_i="18100" xml_f="18101" txt_i="10479" txt_f="10480">x</offsets></italic><offsets xml_i="18110" xml_f="18118" txt_i="10480" txt_f="10488"> + 6.9, </offsets><italic><offsets xml_i="18126" xml_f="18127" txt_i="10488" txt_f="10489">r</offsets></italic><sup><offsets xml_i="18141" xml_f="18142" txt_i="10489" txt_f="10490">2</offsets></sup><offsets xml_i="18148" xml_f="18285" txt_i="10490" txt_f="10627"> = 0.08). Of all patients weighing more than 67.5 kg, 40% of nonexpressers was above the target range and 25% was below the target range.</offsets></p></sec><sec><title><offsets xml_i="18307" xml_f="18310" txt_i="10629" txt_f="10632">BMI</offsets></title><p><offsets xml_i="18321" xml_f="18486" txt_i="10633" txt_f="10798">In the SDG, the nonexpressers were overexposed if the BMI increased, whereas, paradoxically, the expressers had fairly stable exposure regardless of BMI (see Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="18516" xml_f="18517" txt_i="10798" txt_f="10799">2</offsets></xref><offsets xml_i="18524" xml_f="18600" txt_i="10799" txt_f="10875">A). In the GBG, a considerable amount of expressers was overexposed (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="18630" xml_f="18631" txt_i="10875" txt_f="10876">2</offsets></xref><offsets xml_i="18638" xml_f="18721" txt_i="10876" txt_f="10959">B), whereas the nonexpressers were below target if the BMI was lower than 22.3 kg/m</offsets><sup><offsets xml_i="18726" xml_f="18727" txt_i="10959" txt_f="10960">2</offsets></sup><offsets xml_i="18733" xml_f="18782" txt_i="10960" txt_f="11009"> and above target if it was higher than 33.2 kg/m</offsets><sup><offsets xml_i="18787" xml_f="18788" txt_i="11009" txt_f="11010">2</offsets></sup><offsets xml_i="18794" xml_f="18796" txt_i="11010" txt_f="11012"> (</offsets><italic><offsets xml_i="18804" xml_f="18805" txt_i="11012" txt_f="11013">y</offsets></italic><offsets xml_i="18814" xml_f="18822" txt_i="11013" txt_f="11021"> = 0.46 </offsets><italic><offsets xml_i="18830" xml_f="18831" txt_i="11021" txt_f="11022">x</offsets></italic><offsets xml_i="18840" xml_f="18849" txt_i="11022" txt_f="11031"> − 0.26, </offsets><italic><offsets xml_i="18857" xml_f="18858" txt_i="11031" txt_f="11032">r</offsets></italic><sup><offsets xml_i="18872" xml_f="18873" txt_i="11032" txt_f="11033">2</offsets></sup><offsets xml_i="18879" xml_f="18888" txt_i="11033" txt_f="11042"> = 0.15).</offsets></p><fig id="F2" position="float"><label><offsets xml_i="18929" xml_f="18937" txt_i="11043" txt_f="11051">FIGURE 2</offsets></label><caption><p><offsets xml_i="18957" xml_f="18986" txt_i="11051" txt_f="11080">The association between BMI, </offsets><italic><offsets xml_i="18994" xml_f="19000" txt_i="11080" txt_f="11086">CYP3A5</offsets></italic><offsets xml_i="19009" xml_f="19028" txt_i="11086" txt_f="11105"> genotype and Tac C</offsets><sub><offsets xml_i="19033" xml_f="19034" txt_i="11105" txt_f="11106">0</offsets></sub><offsets xml_i="19040" xml_f="19327" txt_i="11106" txt_f="11393"> on day 3 after transplantation, with the target level of 10 to 15 ng/mL shown (shaded area). A, Patients who received 0.20 mg/kg Tac. B, Patients who received Tac in a dose of 0.15 mg/kg (CYP3A5 nonexpressers) or 0.30 mg/kg (CYP3A5 expressers). C, All patients scaled to 0.2 mg/kg dose.</offsets></p></caption><graphic xlink:href="txd-3-e129-g003"></graphic></fig><p><offsets xml_i="19398" xml_f="19513" txt_i="11394" txt_f="11509">When scaled to the theoretical standard dose, a considerable amount (36%) of nonexpressers was overexposed (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19543" xml_f="19544" txt_i="11509" txt_f="11510">2</offsets></xref><offsets xml_i="19551" xml_f="19632" txt_i="11510" txt_f="11591">C). The correlation line crosses the upper limit of the target range at 24.5 kg/m</offsets><sup><offsets xml_i="19637" xml_f="19638" txt_i="11591" txt_f="11592">2</offsets></sup><offsets xml_i="19644" xml_f="19682" txt_i="11592" txt_f="11630"> (calculated with the regression line </offsets><italic><offsets xml_i="19690" xml_f="19691" txt_i="11630" txt_f="11631">y</offsets></italic><offsets xml_i="19700" xml_f="19707" txt_i="11631" txt_f="11638"> = 0.59</offsets><italic><offsets xml_i="19715" xml_f="19716" txt_i="11638" txt_f="11639">x</offsets></italic><offsets xml_i="19725" xml_f="19734" txt_i="11639" txt_f="11648"> + 0.53, </offsets><italic><offsets xml_i="19742" xml_f="19743" txt_i="11648" txt_f="11649">r</offsets></italic><sup><offsets xml_i="19757" xml_f="19758" txt_i="11649" txt_f="11650">2</offsets></sup><offsets xml_i="19764" xml_f="19823" txt_i="11650" txt_f="11709"> = 0.17). Of all patients with a BMI greater than 24.5 kg/m</offsets><sup><offsets xml_i="19828" xml_f="19829" txt_i="11709" txt_f="11710">2</offsets></sup><offsets xml_i="19835" xml_f="19912" txt_i="11710" txt_f="11787">, 44% of nonexpressers were above the target range and 24% were below target.</offsets></p><p><offsets xml_i="19919" xml_f="19970" txt_i="11788" txt_f="11839">Overweight patients with a BMI greater than 25 kg/m</offsets><sup><offsets xml_i="19975" xml_f="19976" txt_i="11839" txt_f="11840">2</offsets></sup><offsets xml_i="19982" xml_f="20103" txt_i="11840" txt_f="11961"> took a median of 6 days to reach the target concentration, compared with 4.5 days in patients with a normal bodyweight (</offsets><italic><offsets xml_i="20111" xml_f="20112" txt_i="11961" txt_f="11962">P</offsets></italic><offsets xml_i="20121" xml_f="20131" txt_i="11962" txt_f="11972"> = 0.083).</offsets></p></sec><sec><title><offsets xml_i="20153" xml_f="20170" txt_i="11974" txt_f="11991">Dosing Guidelines</offsets></title><p><offsets xml_i="20181" xml_f="20255" txt_i="11992" txt_f="12066">Dosing guidelines for overweight patients based on BMI are shown in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="20287" xml_f="20288" txt_i="12066" txt_f="12067">2</offsets></xref><offsets xml_i="20295" xml_f="20348" txt_i="12067" txt_f="12120">. The recommendations were calculated with a target C</offsets><sub><offsets xml_i="20353" xml_f="20354" txt_i="12120" txt_f="12121">0</offsets></sub><offsets xml_i="20360" xml_f="20440" txt_i="12121" txt_f="12201"> of 10 to 15 ng/mL on day 3. A distinction is made between patients in whom the </offsets><italic><offsets xml_i="20448" xml_f="20454" txt_i="12201" txt_f="12207">CYP3A5</offsets></italic><offsets xml_i="20463" xml_f="20554" txt_i="12207" txt_f="12298"> genotype status is known and in whom it is unknown. In accordance with the CPIC guideline,</offsets><sup><xref rid="bib17" ref-type="bibr"><offsets xml_i="20593" xml_f="20595" txt_i="12298" txt_f="12300">17</offsets></xref></sup><offsets xml_i="20608" xml_f="20808" txt_i="12300" txt_f="12500"> it is not common practice in most centers to genotype patients before transplantation, therefore the guideline for unknown genotype was developed. Unfortunately, there was not a sufficient number of </offsets><italic><offsets xml_i="20816" xml_f="20822" txt_i="12500" txt_f="12506">CYP3A5</offsets></italic><offsets xml_i="20831" xml_f="21101" txt_i="12506" txt_f="12776"> expressers in our population to be able to calculate specific dosing guidelines based on BMI for this group. No guidelines for patients with a BMI greater than 35 could be developed due to a lack of patients in this category. For a typical patient with a BMI of 28 kg/m</offsets><sup><offsets xml_i="21106" xml_f="21107" txt_i="12776" txt_f="12777">2</offsets></sup><offsets xml_i="21113" xml_f="21129" txt_i="12777" txt_f="12793"> and an unknown </offsets><italic><offsets xml_i="21137" xml_f="21143" txt_i="12793" txt_f="12799">CYP3A5</offsets></italic><offsets xml_i="21152" xml_f="21290" txt_i="12799" txt_f="12937"> genotype, the dose should be 0.17 mg/kg (85%) if the standard starting dose is 0.20 mg/kg based on the developed dosing guideline (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="21322" xml_f="21323" txt_i="12937" txt_f="12938">2</offsets></xref><offsets xml_i="21330" xml_f="21422" txt_i="12938" txt_f="13030">). If this same patient is a known CYP3A5 nonexpresser, the dose should be 0.16 mg/kg (80%).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="21470" xml_f="21477" txt_i="13031" txt_f="13038">TABLE 2</offsets></label><caption><p><offsets xml_i="21497" xml_f="21552" txt_i="13038" txt_f="13093">Dosing guidelines (mg/kg) based on a patient’s BMI and </offsets><italic><offsets xml_i="21560" xml_f="21566" txt_i="13093" txt_f="13099">CYP3A5</offsets></italic><offsets xml_i="21575" xml_f="21584" txt_i="13099" txt_f="13108"> genotype</offsets></p></caption><graphic xlink:href="txd-3-e129-g004"></graphic></table-wrap><p><offsets xml_i="21662" xml_f="21799" txt_i="13109" txt_f="13246">The recommended dosing guidelines were validated retrospectively in an independent cohort of patients that participated in the FDCC study</offsets><sup><xref rid="bib16" ref-type="bibr"><offsets xml_i="21838" xml_f="21840" txt_i="13246" txt_f="13248">16</offsets></xref></sup><offsets xml_i="21853" xml_f="22035" txt_i="13248" txt_f="13430"> by comparing the percentage on target before and after utilization of the guideline, and the median Tac concentration on day 3 after transplantation. The results are shown in Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="22067" xml_f="22068" txt_i="13430" txt_f="13431">3</offsets></xref><offsets xml_i="22075" xml_f="22080" txt_i="13431" txt_f="13436">. If </offsets><italic><offsets xml_i="22088" xml_f="22094" txt_i="13436" txt_f="13442">CYP3A5</offsets></italic><offsets xml_i="22103" xml_f="22566" txt_i="13442" txt_f="13905"> genotype is unknown, 21.8% of overweight patients were on target before utilization of the guideline, and 32.7% afterward. The percentage of patients overexposed dropped from 70.9% to 47.2%. Especially overweight patients (BMI, 25-30) benefit of the dosing guideline with 16.7% of patients on target before, and 31% after applying the dosing guideline. The percentage of patients on target before and after utilization of the dosing guideline is shown in Figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="22596" xml_f="22597" txt_i="13905" txt_f="13906">3</offsets></xref><offsets xml_i="22604" xml_f="22657" txt_i="13906" txt_f="13959">. When underweight patients (BMI smaller than 20 kg/m</offsets><sup><offsets xml_i="22662" xml_f="22663" txt_i="13959" txt_f="13960">2</offsets></sup><offsets xml_i="22669" xml_f="22792" txt_i="13960" txt_f="14083">) were excluded from the analysis, the proportion of patients overexposed and on target remained the same (data not shown).</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="22840" xml_f="22847" txt_i="14084" txt_f="14091">TABLE 3</offsets></label><caption><p><offsets xml_i="22867" xml_f="22916" txt_i="14091" txt_f="14140">Validation of the dosing guidelines: median Tac C</offsets><sub><offsets xml_i="22921" xml_f="22922" txt_i="14140" txt_f="14141">0</offsets></sub><offsets xml_i="22928" xml_f="22936" txt_i="14141" txt_f="14149"> (ng/mL)</offsets></p></caption><graphic xlink:href="txd-3-e129-g005"></graphic></table-wrap><fig id="F3" position="float"><label><offsets xml_i="23048" xml_f="23056" txt_i="14150" txt_f="14158">FIGURE 3</offsets></label><caption><p><offsets xml_i="23076" xml_f="23266" txt_i="14158" txt_f="14348">The percentage of patients underexposed, on target and overexposed before and after utilization of the developed dosing guideline in a validation cohort of patients with an unknown genotype.</offsets></p></caption><graphic xlink:href="txd-3-e129-g006"></graphic></fig></sec></sec><sec sec-type="discussions"><title><offsets xml_i="23381" xml_f="23391" txt_i="14351" txt_f="14361">DISCUSSION</offsets></title><p><offsets xml_i="23402" xml_f="23870" txt_i="14362" txt_f="14830">This study demonstrates that dosing Tac solely on bodyweight results in overexposure in a considerable proportion of patients. This is especially the case for overweight and obese patients. Based on the goodness of fit, the association between BMI and Tac exposure seems stronger than the one between bodyweight and Tac. To our knowledge, only 2 studies have investigated the relationship between bodyweight or BMI and Tac exposure at first steady state. Rodrigo et al</offsets><sup><xref rid="bib9" ref-type="bibr"><offsets xml_i="23908" xml_f="23909" txt_i="14830" txt_f="14831">9</offsets></xref></sup><offsets xml_i="23922" xml_f="24033" txt_i="14831" txt_f="14942"> concluded that overweight renal transplant recipients are more prone to develop initial high exposure (ie, a C</offsets><sub><offsets xml_i="24038" xml_f="24039" txt_i="14942" txt_f="14943">0</offsets></sub><offsets xml_i="24045" xml_f="24114" txt_i="14943" txt_f="15009"> &gt; 15 ng/mL) compared with nonoverweight recipients. Rodrigo et al</offsets><sup><xref rid="bib9" ref-type="bibr"><offsets xml_i="24152" xml_f="24153" txt_i="15009" txt_f="15010">9</offsets></xref></sup><offsets xml_i="24166" xml_f="24200" txt_i="15010" txt_f="15044"> demonstrated that the first Tac C</offsets><sub><offsets xml_i="24205" xml_f="24206" txt_i="15044" txt_f="15045">0</offsets></sub><offsets xml_i="24212" xml_f="24312" txt_i="15045" txt_f="15145"> tended to be higher than 15 ng/mL in overweight, older kidney transplant recipients. Sawamoto et al</offsets><sup><xref rid="bib18" ref-type="bibr"><offsets xml_i="24351" xml_f="24353" txt_i="15145" txt_f="15147">18</offsets></xref></sup><offsets xml_i="24366" xml_f="24461" txt_i="15147" txt_f="15242"> demonstrated that the average Tac maintenance dose in patients with a BMI greater than 25 kg/m</offsets><sup><offsets xml_i="24466" xml_f="24467" txt_i="15242" txt_f="15243">2</offsets></sup><offsets xml_i="24473" xml_f="24549" txt_i="15243" txt_f="15319"> is significantly lower compared with that in patients with a BMI of 25 kg/m</offsets><sup><offsets xml_i="24554" xml_f="24555" txt_i="15319" txt_f="15320">2</offsets></sup><offsets xml_i="24561" xml_f="24610" txt_i="15320" txt_f="15369"> or less. Our study substantiates these findings.</offsets></p><p><offsets xml_i="24617" xml_f="25027" txt_i="15370" txt_f="15780">Dosing guidelines for overweight and obese patients were developed and validated for patients with an unknown genotype and CYP3A5 nonexpressers. As a validation cohort we used patients who participated in the FDCC trial. In this multicenter study, Tac was dosed according to local clinical practice, and as a consequence, this is a very heterogeneous group. Despite this, we managed to validate our guidelines.</offsets></p><p><offsets xml_i="25034" xml_f="25473" txt_i="15781" txt_f="16220">Unfortunately, no dosing guideline could be developed for CYP3A5 expressers because there were too few CYP3A5 expressers in our population. Also, insufficient obese patients with a BMI greater than 35 were available to validate the dosing guideline in that group. Establishing separate dosing guidelines for overweight patients is not unusual. Other drugs, such as aminoglycosides, are dosed using ideal body weight in overweight patients.</offsets><sup><xref rid="bib19" ref-type="bibr"><offsets xml_i="25512" xml_f="25514" txt_i="16220" txt_f="16222">19</offsets></xref></sup><offsets xml_i="25527" xml_f="25956" txt_i="16222" txt_f="16651"> However, aminoglycosides are hydrophilic drugs, whereas Tac is lipophilic. Overweight patients have a larger fat compartment, and therefore, adjusting the dose of hydrophilic drugs based on total bodyweight would lead to overexposure. However, for lipophilic drugs, a larger volume of distribution would be expected in overweight patients, and therefore, choosing the dose based on total bodyweight seems logical. Miyamoto et al</offsets><sup><xref rid="bib20" ref-type="bibr"><offsets xml_i="25995" xml_f="25997" txt_i="16651" txt_f="16653">20</offsets></xref></sup><offsets xml_i="26010" xml_f="26445" txt_i="16653" txt_f="17088"> demonstrated that the Tac concentration in fat tissue was lower than what one would expect based on the lipophilicity of the drug. This substantiates the present finding that the Tac dose should not be entirely based on bodyweight in obese patients. An explanation for this counterintuitive finding could be that Tac is extensively distributed into erythrocytes which have a high content of FK-binding proteins to the receptor of Tac.</offsets><sup><xref rid="bib4" ref-type="bibr"><offsets xml_i="26483" xml_f="26484" txt_i="17088" txt_f="17089">4</offsets></xref></sup><offsets xml_i="26497" xml_f="26741" txt_i="17089" txt_f="17333"> Although with an increasing bodyweight, the blood plasma volume also increases, this occurs to a lesser extent. Theoretically, the Tac initial dose should be based on this increase in blood plasma volume rather than the increase in bodyweight.</offsets></p><p><offsets xml_i="26748" xml_f="26965" txt_i="17334" txt_f="17551">To our knowledge, this is the first study to give dosing guidelines for overweight and obese transplant recipients. A subject for future research could be the influence of other genetic polymorphisms in, for example, </offsets><italic><offsets xml_i="26973" xml_f="26979" txt_i="17551" txt_f="17557">CYP3A4</offsets></italic><offsets xml_i="26988" xml_f="27060" txt_i="17557" txt_f="17629"> which has also been associated with altered Tac clearance. Especially, </offsets><italic><offsets xml_i="27068" xml_f="27077" txt_i="17629" txt_f="17638">CYP3A4*22</offsets></italic><offsets xml_i="27086" xml_f="27179" txt_i="17638" txt_f="17731"> is interesting because it is associated with a lower Tac dosage after renal transplantation.</offsets><sup><xref rid="bib21" ref-type="bibr"><offsets xml_i="27218" xml_f="27220" txt_i="17731" txt_f="17733">21</offsets></xref></sup></p><p><offsets xml_i="27240" xml_f="27655" txt_i="17734" txt_f="18149">The biggest limitation of this study is that it is a post hoc analysis. It was unplanned and therefore the apparent differences and associations could be coincidental. The second limitation is that more than three quarters of the studied population was white, and only 10% was from African descent. Research has shown that African-American kidney transplant recipients require a higher Tac dose regardless of their </offsets><italic><offsets xml_i="27663" xml_f="27669" txt_i="18149" txt_f="18155">CYP3A5</offsets></italic><offsets xml_i="27678" xml_f="27688" txt_i="18155" txt_f="18165"> genotype.</offsets><sup><xref rid="bib22" ref-type="bibr"><offsets xml_i="27727" xml_f="27729" txt_i="18165" txt_f="18167">22</offsets></xref><offsets xml_i="27736" xml_f="27737" txt_i="18167" txt_f="18168">,</offsets><xref rid="bib23" ref-type="bibr"><offsets xml_i="27771" xml_f="27773" txt_i="18168" txt_f="18170">23</offsets></xref></sup><offsets xml_i="27786" xml_f="28311" txt_i="18170" txt_f="18695"> The third limitation is that Tac concentrations were measured with immunoassays, instead of using mass spectrometry which is nowadays considered the criterion standard. In our center, immunoassays were used for the routine determination of Tac at the start of the trial. Many transplant centers worldwide still rely on immunoassays for TDM of Tac. The final limitation is that the target range of 10 to 15 ng/mL we aimed for may now be regarded as rather high although the precise therapeutic range for Tac is still unclear.</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="28350" xml_f="28352" txt_i="18695" txt_f="18697">24</offsets></xref><offsets xml_i="28359" xml_f="28360" txt_i="18697" txt_f="18698">-</offsets><xref rid="bib27" ref-type="bibr"><offsets xml_i="28394" xml_f="28396" txt_i="18698" txt_f="18700">27</offsets></xref></sup></p><p><offsets xml_i="28416" xml_f="28681" txt_i="18701" txt_f="18966">In conclusion, basing the Tac starting dose solely on bodyweight leads to overexposure in more than one third of patients, and over half of overweight or obese patients. Basing the Tac starting dose on BMI in overweight patients, whether or not in combination with </offsets><italic><offsets xml_i="28689" xml_f="28695" txt_i="18966" txt_f="18972">CYP3A5</offsets></italic><offsets xml_i="28704" xml_f="28776" txt_i="18972" txt_f="19044"> genotype, could reduce overexposure of Tac early after transplantation.</offsets></p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors are grateful to the research nurses Mrs. M.J. Boer -Verschragen, Ms. M. Cadogan, and Mrs. N.J. de Leeuw -van Weenen for their valuable contribution to this clinical study. The authors are appreciative of the work conducted by the co-authors of the original study, for without them this post hoc analysis would not have been possible. The original study was an investigator-initiated study. All authors had full access to all the data and have full responsibility for the contents of this publication and the decision to submit for publication.</p></ack><fn-group><fn fn-type="other"><p>Published online 19 January, 2017.</p></fn><fn fn-type="COI-statement"><p>T. van Gelder has received lecture fees from Chiesi Pharmaceuticals and Astellas Pharma B.V., and consulting fees from Astellas Pharma B.V., Novartis Pharma B.V., Roche Pharma, Teva Pharma and Sandoz Pharma. D.A. Hesselink has received lecture and consulting fees, as well as grant support from Astellas Pharma B.V., Bristol-Myers Squibb, Chiesi Pharmaceuticals, MSD Pharmaceuticals, Novartis Pharma B.V., and Roche Pharma. The other authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>Mrs. Bouamar received a grant (grant number 017006041) from The Netherlands Organization for Scientific Research (NWO) (grant number 017006041). Ms. Shuker received a grant (grant number IP11.44) from the Dutch Kidney Foundation (Nierstichting Nederland).</p></fn><fn fn-type="COI-statement"><p>The authors declare no conflicts of interest.</p></fn><fn fn-type="other"><p>L.A., B.W., T.G. and D.H. contributed to the design of the work and wrote the manuscript. R.B. and N.S. collected data. B.K and R.S enabled data collection. L.A. performed the analyses. J.T., R.B., N.S., R.S., B.K., wrote the manuscript. All authors gave final approval of the version to be published.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="bib1"><label>1</label><mixed-citation publication-type="journal"><collab collab-type="authors">Kidney Disease: Improving Global Outcomes Transplant Work G</collab>. <article-title>KDIGO clinical practice guideline for the care of kidney transplant recipients</article-title>. <source><italic>Am J Transplant</italic></source>. <year>2009</year>;<volume>9</volume>:<fpage>S1</fpage>–<lpage>S155</lpage>.</mixed-citation></ref><ref id="bib2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Starzl</surname><given-names>TE</given-names></name><name><surname>Todo</surname><given-names>S</given-names></name><name><surname>Fung</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>FK 506 for liver, kidney, and pancreas transplantation</article-title>. <source><italic>Lancet</italic></source>. <year>1989</year>;<volume>2</volume>:<fpage>1000</fpage>–<lpage>1004</lpage>.<pub-id pub-id-type="pmid">2478846</pub-id></mixed-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Jusko</surname><given-names>WJ</given-names></name><name><surname>Thomson</surname><given-names>AW</given-names></name><name><surname>Fung</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Consensus document: therapeutic monitoring of tacrolimus (FK-506)</article-title>. <source><italic>Ther Drug Monit</italic></source>. <year>1995</year>;<volume>17</volume>:<fpage>606</fpage>–<lpage>614</lpage>.<pub-id pub-id-type="pmid">8588229</pub-id></mixed-citation></ref><ref id="bib4"><label>4</label><mixed-citation publication-type="webpage"><collab collab-type="authors">Astellas Pharma U, Inc</collab>. <article-title>PROGRAF Tacrolimus capsules, tacrolimus injection (for intravenous infusion only)</article-title>. <year>2009</year>
<comment>&lt;<ext-link ext-link-type="uri" xlink:href="https://www.astellas.us/docs/prograf.pdf">https://www.astellas.us/docs/prograf.pdf</ext-link>&gt;</comment>.</mixed-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Staatz</surname><given-names>CE</given-names></name><name><surname>Tett</surname><given-names>SE</given-names></name></person-group>
<article-title>Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation</article-title>. <source><italic>Clin Pharmacokinet</italic></source>. <year>2004</year>;<volume>43</volume>:<fpage>623</fpage>–<lpage>653</lpage>.<pub-id pub-id-type="pmid">15244495</pub-id></mixed-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Thervet</surname><given-names>E</given-names></name><name><surname>Loriot</surname><given-names>MA</given-names></name><name><surname>Barbier</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Optimization of initial tacrolimus dose using pharmacogenetic testing</article-title>. <source><italic>Clin Pharmacol Ther</italic></source>. <year>2010</year>;<volume>87</volume>:<fpage>721</fpage>–<lpage>726</lpage>.<pub-id pub-id-type="pmid">20393454</pub-id></mixed-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Press</surname><given-names>RR</given-names></name><name><surname>Ploeger</surname><given-names>BA</given-names></name><name><surname>den Hartigh</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients</article-title>. <source><italic>Ther Drug Monit</italic></source>. <year>2009</year>;<volume>31</volume>:<fpage>187</fpage>–<lpage>197</lpage>.<pub-id pub-id-type="pmid">19258929</pub-id></mixed-citation></ref><ref id="bib8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Kausman</surname><given-names>JY</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Marks</surname><given-names>SD</given-names></name></person-group>
<article-title>Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients</article-title>. <source><italic>Pediatr Transplant</italic></source>. <year>2008</year>;<volume>12</volume>:<fpage>329</fpage>–<lpage>335</lpage>.<pub-id pub-id-type="pmid">18435608</pub-id></mixed-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Rodrigo</surname><given-names>E</given-names></name><name><surname>de Cos</surname><given-names>MA</given-names></name><name><surname>Sánchez</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>High initial blood levels of tacrolimus in overweight renal transplant recipients</article-title>. <source><italic>Transplant Proc</italic></source>. <year>2005</year>;<volume>37</volume>:<fpage>1453</fpage>–<lpage>1454</lpage>.<pub-id pub-id-type="pmid">15866635</pub-id></mixed-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Størset</surname><given-names>E</given-names></name><name><surname>Holford</surname><given-names>N</given-names></name><name><surname>Hennig</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling</article-title>. <source><italic>Br J Clin Pharmacol</italic></source>. <year>2014</year>;<volume>78</volume>:<fpage>509</fpage>–<lpage>523</lpage>.<pub-id pub-id-type="pmid">25279405</pub-id></mixed-citation></ref><ref id="bib11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Friedman</surname><given-names>AN</given-names></name><name><surname>Miskulin</surname><given-names>DC</given-names></name><name><surname>Rosenberg</surname><given-names>IH</given-names></name><etal></etal></person-group>
<article-title>Demographics and trends in overweight and obesity in patients at time of kidney transplantation</article-title>. <source><italic>Am J Kidney Dis</italic></source>. <year>2003</year>;<volume>41</volume>:<fpage>480</fpage>–<lpage>487</lpage>.<pub-id pub-id-type="pmid">12552513</pub-id></mixed-citation></ref><ref id="bib12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Lafranca</surname><given-names>JA</given-names></name><name><surname>IJermans</surname><given-names>JN</given-names></name><name><surname>Betjes</surname><given-names>MG</given-names></name><etal></etal></person-group>
<article-title>Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis</article-title>. <source><italic>BMC Med</italic></source>. <year>2015</year>;<volume>13</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">25963131</pub-id></mixed-citation></ref><ref id="bib13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Passey</surname><given-names>C</given-names></name><name><surname>Birnbaum</surname><given-names>AK</given-names></name><name><surname>Brundage</surname><given-names>RC</given-names></name><etal></etal></person-group>
<article-title>Dosing equation for tacrolimus using genetic variants and clinical factors</article-title>. <source><italic>Br J Clin Pharmacol</italic></source>. <year>2011</year>;<volume>72</volume>:<fpage>948</fpage>–<lpage>957</lpage>.<pub-id pub-id-type="pmid">21671989</pub-id></mixed-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Andrews</surname><given-names>LM</given-names></name><name><surname>Riva</surname><given-names>N</given-names></name><name><surname>de Winter</surname><given-names>BC</given-names></name><etal></etal></person-group>
<article-title>Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients</article-title>. <source><italic>Expert Opin Drug Metab Toxicol</italic></source>. <year>2015</year>;<volume>11</volume>:<fpage>921</fpage>–<lpage>936</lpage>.<pub-id pub-id-type="pmid">25865963</pub-id></mixed-citation></ref><ref id="bib15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Shuker</surname><given-names>N</given-names></name><name><surname>Bouamar</surname><given-names>R</given-names></name><name><surname>van Schaik</surname><given-names>RH</given-names></name><etal></etal></person-group>
<article-title>A Randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation</article-title>. <source><italic>Am J Transplant</italic></source>. <year>2016</year>;<volume>16</volume>:<fpage>2085</fpage>–<lpage>2096</lpage>.<pub-id pub-id-type="pmid">26714287</pub-id></mixed-citation></ref><ref id="bib16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>van Gelder</surname><given-names>T</given-names></name><name><surname>Silva</surname><given-names>HT</given-names></name><name><surname>de Fijter</surname><given-names>JW</given-names></name><etal></etal></person-group>
<article-title>Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial</article-title>. <source><italic>Transplantation</italic></source>. <year>2008</year>;<volume>86</volume>:<fpage>1043</fpage>–<lpage>1051</lpage>.<pub-id pub-id-type="pmid">18946341</pub-id></mixed-citation></ref><ref id="bib17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Birdwell</surname><given-names>KA</given-names></name><name><surname>Decker</surname><given-names>B</given-names></name><name><surname>Barbarino</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing</article-title>. <source><italic>Clin Pharmacol Ther</italic></source>. <year>2015</year>;<volume>98</volume>:<fpage>19</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">25801146</pub-id></mixed-citation></ref><ref id="bib18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Sawamoto</surname><given-names>K</given-names></name><name><surname>Huong</surname><given-names>TT</given-names></name><name><surname>Sugimoto</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Mechanisms of lower maintenance dose of tacrolimus in obese patients</article-title>. <source><italic>Drug Metab Pharmacokinet</italic></source>. <year>2014</year>;<volume>29</volume>:<fpage>341</fpage>–<lpage>347</lpage>.<pub-id pub-id-type="pmid">24670405</pub-id></mixed-citation></ref><ref id="bib19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Polso</surname><given-names>AK</given-names></name><name><surname>Lassiter</surname><given-names>JL</given-names></name><name><surname>Nagel</surname><given-names>JL</given-names></name></person-group>
<article-title>Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review</article-title>. <source><italic>J Clin Pharm Ther</italic></source>. <year>2014</year>;<volume>39</volume>:<fpage>584</fpage>–<lpage>608</lpage>.<pub-id pub-id-type="pmid">25203631</pub-id></mixed-citation></ref><ref id="bib20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Uno</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres</article-title>. <source><italic>Liver Transpl</italic></source>. <year>2004</year>;<volume>10</volume>:<fpage>392</fpage>–<lpage>396</lpage>.<pub-id pub-id-type="pmid">15004766</pub-id></mixed-citation></ref><ref id="bib21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Tang</surname><given-names>JT</given-names></name><name><surname>Andrews</surname><given-names>LM</given-names></name><name><surname>van Gelder</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations</article-title>. <source><italic>Expert Opin Drug Metab Toxicol</italic></source>. <year>2016</year>;<volume>12</volume>:<fpage>555</fpage>–<lpage>565</lpage>.<pub-id pub-id-type="pmid">27010623</pub-id></mixed-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Sanghavi</surname><given-names>K</given-names></name><name><surname>Brundage</surname><given-names>RC</given-names></name><name><surname>Miller</surname><given-names>MB</given-names></name><etal></etal></person-group>
<article-title>Genotype-guided tacrolimus dosing in African-American kidney transplant recipients</article-title>. <source><italic>Pharmacogenomics J</italic></source>. <year>2015</year>.</mixed-citation></ref><ref id="bib23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Oetting</surname><given-names>WS</given-names></name><name><surname>Schladt</surname><given-names>DP</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Genomewide Association Study of Tacrolimus Concentrations in African American Kidney transplant recipients identifies multiple CYP3A5 alleles</article-title>. <source><italic>Am J Transplant</italic></source>. <year>2016</year>;<volume>16</volume>:<fpage>574</fpage>–<lpage>582</lpage>.<pub-id pub-id-type="pmid">26485092</pub-id></mixed-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Ekberg</surname><given-names>H</given-names></name><name><surname>Tedesco-Silva</surname><given-names>H</given-names></name><name><surname>Demirbas</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Reduced exposure to calcineurin inhibitors in renal transplantation</article-title>. <source><italic>N Engl J Med</italic></source>. <year>2007</year>;<volume>357</volume>:<fpage>2562</fpage>–<lpage>2575</lpage>.<pub-id pub-id-type="pmid">18094377</pub-id></mixed-citation></ref><ref id="bib25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Bouamar</surname><given-names>R</given-names></name><name><surname>Shuker</surname><given-names>N</given-names></name><name><surname>Hesselink</surname><given-names>DA</given-names></name><etal></etal></person-group>
<article-title>Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†)</article-title>. <source><italic>Am J Transplant</italic></source>. <year>2013</year>;<volume>13</volume>:<fpage>1253</fpage>–<lpage>1261</lpage>.<pub-id pub-id-type="pmid">23480233</pub-id></mixed-citation></ref><ref id="bib26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Opelz</surname><given-names>G</given-names></name><name><surname>Döhler</surname><given-names>B</given-names></name></person-group>
<article-title>Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant</article-title>. <source><italic>Transplantation</italic></source>. <year>2008</year>;<volume>86</volume>:<fpage>371</fpage>–<lpage>376</lpage>.<pub-id pub-id-type="pmid">18698238</pub-id></mixed-citation></ref><ref id="bib27"><label>27</label><mixed-citation publication-type="webpage"><article-title>CTS Collaborative Transplant Study Newsletter 1:2014</article-title>. 
<comment><ext-link ext-link-type="uri" xlink:href="http://wwwctstransplantorg/public/newsletters/2014/pdf/2014-1pdf">http://www.ctstransplantorg/public/newsletters/2014/pdf/2014-1pdf</ext-link></comment>.</mixed-citation></ref></ref-list></back></article>